Supernus Pharmaceuticals Targeted in Ransomware Incident
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced it was targeted by a ransomware attack that began around mid-November 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced it was targeted by a ransomware attack that began around mid-November 2021. The Company reported that the attack had no significant impact on its operations and that no ransom payments were made. Following detection, it engaged cybersecurity experts and successfully recovered the affected files. The Company remains vigilant, monitoring the situation and ensuring the protection of any confidential information. Despite the incident, Supernus continues to operate normally as it develops treatments for CNS diseases.
Positive
- The Company successfully recovered all impacted files from the ransomware attack.
- No ransom payments were made, indicating effective incident management.
- Operations continue without interruption, maintaining business continuity.
Negative
- There is a potential risk of further attacks that could impact business operations.
Details
News Market Reaction – SUPN
The recorded move for SUPN in the trading session of this news was -4.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations
No ransom payments have been made by the Company
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious disruption to the Company’s operations. The Company continues to operate without interruption and does not currently anticipate paying any ransom amounts to any criminal ransomware group.
The Company currently believes the incident began around mid-November, 2021. Based on the preliminary results of the ongoing investigation, the Company believes the criminal ransomware group encrypted certain files on the Company’s systems, deployed malware to impede access to the Company’s systems, and thereafter threatened to publish certain data copied from the Company’s systems. Upon detection of the ransomware, the Company notified government authorities, engaged cybersecurity experts and its outside law firm, and commenced its recovery process. The Company successfully recovered the impacted files and has taken additional steps designed to further protect its networks and files.
To date, the Company has not paid any ransom and has been able to restore all of the information encrypted by the criminal ransomware group.
Although to date the Company’s business and operations have not been significantly impacted by the incident, there is no assurance that further attacks may not significantly impact the Company’s business or operations and that information improperly obtained by the criminal ransomware group may not be exploited by the criminal ransomware group or other third parties. The Company will take appropriate action to protect any stolen confidential information and will continue to investigate the incident and monitor the situation going forward.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.